USP20 as a key regulator of immunosuppression and a novel predictor of poor prognosis in lung adenocarcinoma
Longhao Wang, Danni Qiao, Ruixue Gu, Qingyu Zhang, Yan Guo, Lina Liu, Mingqi Zhu, Yaliang Fan, Peng Zhang, Qiongyang Lv, Junya Yan, Shundong Cang · 2026
Read USP20 as a key regulator of immunosuppression and a novel predictor of poor prognosis in lung adenocarcinoma by Longhao Wang, Danni Qiao, Ruixue Gu, Qingyu Zhang, Yan Guo, Lina Liu, Mingqi Zhu, Yaliang Fan, Peng Zhang, Qiongyang Lv, Junya Yan, Shundong Cang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13501859.txt.
Description
Longhao Wang leads a twelve-author team reporting a 2026 study of the enzyme USP20 as a driver of immune suppression and poor outlook in lung adenocarcinoma. The team profiled the gene across the TCGA, GTEx, and GEO cohorts, checked survival with Kaplan-Meier and Cox models, and mapped the immune landscape with estimation algorithms. Single-cell datasets resolved which cell types carry it, and tissue staining plus cell and animal experiments tested the biology.
USP20 ran high in tumours compared with normal lung, and patients with the highest levels survived less well, with the gene standing as an independent risk factor. Its copies were more often amplified than mutated. High expression came with reshaped immune cell mixtures, more suppressive populations, and higher checkpoint molecule levels. Laboratory work confirmed the protein pushes cancer cell growth and migration. The authors nominate USP20 as a prognostic marker and an immunotherapy target.
Catalog record
| CREATOR | Longhao Wang, Danni Qiao, Ruixue Gu, Qingyu Zhang, Yan Guo, Lina Liu, Mingqi Zhu, Yaliang Fan, Peng Zhang, Qiongyang Lv, Junya Yan, Shundong Cang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 60823 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |